Blueshift Asset Management LLC Invests $776,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

Blueshift Asset Management LLC acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 2,326 shares of the company's stock, valued at approximately $776,000.

Several other large investors have also recently added to or reduced their stakes in MEDP. DT Investment Partners LLC acquired a new stake in shares of Medpace in the second quarter valued at approximately $41,000. Ashton Thomas Securities LLC acquired a new position in Medpace in the 3rd quarter valued at $37,000. Ashton Thomas Private Wealth LLC bought a new stake in shares of Medpace during the 2nd quarter valued at $52,000. Capital Performance Advisors LLP bought a new stake in shares of Medpace during the 3rd quarter valued at $46,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of Medpace during the 2nd quarter worth $61,000. Institutional investors own 77.98% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Robert W. Baird upped their price objective on shares of Medpace from $349.00 to $354.00 and gave the stock a "neutral" rating in a research report on Monday. Redburn Atlantic initiated coverage on shares of Medpace in a research report on Monday, October 14th. They issued a "buy" rating and a $404.00 target price for the company. Baird R W lowered shares of Medpace from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, October 23rd. StockNews.com cut shares of Medpace from a "buy" rating to a "hold" rating in a research note on Friday, September 27th. Finally, Jefferies Financial Group cut Medpace from a "buy" rating to a "hold" rating and cut their target price for the stock from $415.00 to $345.00 in a research note on Wednesday, September 25th. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, Medpace currently has an average rating of "Hold" and a consensus price target of $380.56.

Medpace Trading Up 1.1 %

Medpace stock traded up $3.75 during mid-day trading on Thursday, reaching $338.96. The company had a trading volume of 191,628 shares, compared to its average volume of 284,718. The business has a fifty day simple moving average of $338.32 and a 200 day simple moving average of $371.75. The company has a market cap of $10.53 billion, a P/E ratio of 29.68, a P/E/G ratio of 1.87 and a beta of 1.37. Medpace Holdings, Inc. has a fifty-two week low of $268.80 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. During the same quarter last year, the business posted $2.22 EPS. Medpace's revenue for the quarter was up 8.3% on a year-over-year basis. Research analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.